Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation  

作　　者：Yang GAO Fei GAO Jimin SHI Huarui FU He HUANG Yanmin ZHAO 

机构地区：[1]Bone Marrow Transplantation Center,the First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou 310003,China [2]Institute of Hematology,Zhejiang University,Hangzhou 310058,China [3]Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy,Hangzhou 310058,China

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2021年第8期695-700,共6页浙江大学学报（英文版）B辑（生物医学与生物技术）

基　　金：supported by the National Natural Science Foundation of China (No. 81670148);the Health Science and Technology Project of Zhejiang Province (No. 2012KYB079), China。

摘　　要：Pure red cell aplasia(PRCA) is a well-recognized complication of ABO major mismatched allogeneic hematopoietic stem cell transplantation(allo-HSCT), with a reported incidence of 10% – 20%(Zhidong et al., 2012;Busca et al., 2018). It is clinically characterized by anemia, reticulocytopenia,and the absence of erythroblasts in a normal-appearing bone marrow biopsy(Shahan and Hildebrandt, 2015).The mechanism for PRCA has been presumed to be persistence of recipient isoagglutinins, produced by residual host B lymphocytes or plasma cells。

关 键 词：ABO al. HEMATOPOIETIC 

分 类 号：R556.5[医药卫生—血液循环系统疾病]